<DOC>
	<DOCNO>NCT02362880</DOCNO>
	<brief_summary>The main purpose study assess safety single dose FBB follow PET scan individual risk genetic Alzheimer 's disease .</brief_summary>
	<brief_title>Study Genetic Alzheimer 's Disease Mutation Carriers Preclinical Stages Disease 18F-Florbetaben Positron Emission Tomography Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Adult child ( &gt; 18 yo ) genetic Alzheimer ? disease patient know mutation PSEN1 , APP PSEN2 gene either cognitively normal ( CDR=0 ) mild symptom cognitive decline ( CDR 0.5 1 ) According principal investigator , participant must commit participate complete study procedure . Has sign Informed Consent Form voluntarily participate study Subjects able complete study . Any major disease history major disease , especially hepatobilliar disease ( AST /ALT ? 5 x ULN ) advance renal insufficiency ( creatinine ? 2 x ULN ) Current previous history alcohol abuse epilepsy Allergic Florbetaben constituent Multiple drug allergy and/or previous history contrast allergy . Pregnancy breast feed plan pregnancy study period Any disease history disease , opinion investigator , cause disturbance brain function ( e.g . vitamin B12 folic acid deficiency , disturb thyroid function ) Evidence neurological psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>